July 19, 2021 05:33 PM EDT

Chinese antibody player chases Hong Kong IPO with lead Rituxan challenger ready for late-stage test

Kyle Blankenship

Oncology R&D has boomed in China with a stable of homegrown biotechs churning out late-stage clinical hopefuls. Much of those have been so-called “me-too” drugs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chinese antibody player chases Hong Kong IPO with lead Rituxan challenger ready for late-stage test

Kyle Blankenship

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

Chi­nese an­ti­body play­er chas­es Hong Kong IPO with lead Rit­ux­an chal­lenger ready for late-stage test

Kyle Blankenship

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Chinese antibody player chases Hong Kong IPO with lead Rituxan challenger ready for late-stage test

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus